Dai Jessica C, Brisbane Wayne G, Chang Helena C, Hsi Ryan S, Harper Jonathan D
Department of Urology, University of Washington, Seattle, WA.
Department of Urology, University of Washington, Seattle, WA.
Urology. 2018 Dec;122:58-63. doi: 10.1016/j.urology.2018.08.029. Epub 2018 Sep 5.
To assess drug reactions (ADRs) encountered by practicing urologists for contrast instilled into the urinary collecting system, and to describe current practice patterns regarding contrast administration into the urinary tract for patients with known contrast allergies.
Endourological Society members were e-mailed a web-based survey about their prior experience with contrast-related ADRs and practices for contrast administration into the urinary tract among patients with known intravenous contrast allergies. Chi-squared analysis was used to compare management patterns between patients with established allergies and those without.
An estimated 2300-2500 e-mails were reached, resulting in an estimated response rate of 6.3%-8%. Over 75% of respondents were fellowship trained. Average time in practice was 16 years, and respondents performed a mean of 6.7 urologic contrast studies per week. Among respondents, 32.6%, 14.7%, and 4.0% had treated at least 1 patient with a mild, moderate, or severe reaction, respectively. Contrast-related ADRs were most commonly associated with retrograde pyelogram (50%). For patients with known contrast allergies, 5.4% pursue additional work-up before administering contrast in the urinary tract. Pretreatment with antihistamine or steroids is used by 24.8% and 23.4%, respectively. When performing retrograde pyelograms for such patients, urologists are more likely to use dilute contrast (P = .003), but otherwise do not significantly alter technique.
Contrast ADRs are encountered not infrequently among practicing urologists. There is notable practice variation in the management of patients with known contrast allergies, though the overall perceived risk of contrast use in these patients is low, provided good technique is used.
评估泌尿外科医生在向泌尿系统收集系统注入造影剂时遇到的药物不良反应(ADR),并描述对于已知对造影剂过敏的患者进行尿路造影剂给药的当前实践模式。
通过电子邮件向腔内泌尿外科协会成员发送了一项基于网络的调查,内容涉及他们既往与造影剂相关ADR的经历以及对已知静脉造影剂过敏患者进行尿路造影剂给药的实践情况。采用卡方分析比较有明确过敏史患者和无过敏史患者的处理模式。
估计发送了2300 - 2500封电子邮件,估计回复率为6.3% - 8%。超过75%的受访者接受过专科培训。平均从业时间为16年,受访者每周平均进行6.7例泌尿外科造影检查。在受访者中,分别有32.6%、14.7%和4.0%的人至少治疗过1例有轻度、中度或重度反应的患者。造影剂相关的ADR最常与逆行肾盂造影有关(50%)。对于已知对造影剂过敏的患者,5.4%的人在进行尿路造影剂给药前会进行额外的检查。分别有24.8%和23.4%的人使用抗组胺药或类固醇进行预处理。在为这类患者进行逆行肾盂造影时,泌尿外科医生更倾向于使用稀释造影剂(P = 0.003),但在其他方面不会显著改变操作技术。
在执业泌尿外科医生中,造影剂ADR并非罕见。对于已知对造影剂过敏的患者,其管理存在显著的实践差异,不过只要使用良好的技术,这些患者使用造影剂的总体感知风险较低。